DSM Biomedical partnered with Cerapedics, a privately held orthobiologics company, to develop a next generation peptide enhanced bone graft.
Here are five things to know:
1. The partnership will align DSM's regenerative materials capabilities with Cerapedics' proprietary synthetic small peptide, P-15, technology. DSM's new bioceramic platform is a carbonated apatite matrix designed for fast, predictable modeling in bone graft substitute applications.
2. DSM will provide a collagen carrier, final packaging and support from concept through commercialization under the new partnership agreement. Cerapedics' first generation product i-Factor Peptide Enhanced Bone Graft has been available outside the U.S. since 2008 and for anterior cervical discectomy and fusion in the U.S. since 2015.
3. Cerapedics plans to use the collaboration to develop and commercialize its next generation technology. "Over the past year we have been focused on accelerating our commercialization efforts in the U.S. following the FDA premarket approval of i-Factor Bone Graft, and we are excited to be partnered with DSM in delivering our next generation product to market," said Cerapedics CEO Glen Kashuba.
4. The next generation product will build on the P-15 technology with potential applications in the lumbar spine.
5. In September, Cerapedics reported two-year follow up data from their FDA investigational device exemption trial of i-Factor for ACDF. Around 97 percent of the patients who received i-Factor reported successful fusion and 77 percent reported lower Neck Disability Index scores.